A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, 4-part, Interwoven Single- and Multiple-ascending Dose Study to Assess Safety, Tolerability, PK and PD of LIK066 in Healthy Subjects and in Patients With T2DM.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jun 2014

At a glance

  • Drugs LIK 066 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 11 Jan 2013 Actual initiation date changed from Jul 2011 to Jun 2011 as reported by ClinicalTrials.gov.
    • 11 Jan 2013 Planned End Date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 11 Jan 2013 Planned number of patients changed from 136 to 168 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top